• Initial reimbursement signals highly encouraging
• Over 90% of submitted claims being paid
• Average payments above Medicare fee schedule rate

Lumos Diagnostics Holdings Ltd (ASX:LDX) has provided an update on the progress of its FebriDx rapid diagnostic test rollout in the U.S. market, following the FDA CLIA waiver clearance. Key highlights include positive reimbursement signals, with over 90% of claims being paid and average payments exceeding the Medicare fee schedule rate of US$41.38 per test. The commercial rollout is progressing well, with FebriDx now in routine use across 44 WellStreet urgent care clinics. Lumos is also evaluating additional pilot sites with new urgent care operators, setting the stage for broader adoption ahead of the 2027/28 U.S. flu season.

null

Lumos Diagnostics anticipates continued progress in the commercialization of FebriDx, with a focus on expanding adoption in urgent care and primary care settings.